The clinical effects of foscarnet prophylaxis for human herpes virus type 6 associated limbic encephalitis after umbilical cord blood transplantatio
Not Applicable
- Conditions
- Human herpes virus type 6-associated limbic encephalitis after umbilical cord blood transplantation
- Registration Number
- JPRN-UMIN000010591
- Lead Sponsor
- Toranomon Hospital Department of Hematology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Hypersensitive for foscarnet 2) Existence of comorbid disease, grade 3 or more in CTCAE v3.0 3) Unsuitable for enrollment judged by attending physian
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of the treatment success defined by the following criteria during the period from transplantation to day 50
- Secondary Outcome Measures
Name Time Method The incidence of human herpes virus type 6-associated limbic encephalitis The overall survival at 100days after cord blood tranplantation The rate of incidence of cytomegalovirus infection